Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2015 Feb;59(2):1329-33. doi: 10.1128/AAC.03937-14. Epub 2014 Nov 24.

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens.

Author information

1
Center for Vaccine Research and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
2
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
3
Division of Pediatric Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington, USA.
4
Center for Vaccine Research and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA rmont@pitt.edu.

Abstract

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

PMID:
25421473
PMCID:
PMC4335883
DOI:
10.1128/AAC.03937-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center